Evoclin is a drug owned by Norvium Bioscience Llc. It is protected by 2 US drug patents filed in 2013 out of which all have expired. Based on its patents and exclusivities, its generic launch date is estimated to be Feb 03, 2024. Details of Evoclin's patents and their expiration are given in the table below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| These drug patents focus on the other aspects of the drug like dosage, mode of administration (oral, tablet, capsules, liquids etc). | |||
| US7141237 | Pharmaceutical foam |
Feb, 2024
(10 months ago) |
Expired
|
| US7374747 | Pharmaceutical foam |
Jan, 2024
(10 months ago) |
Expired
|
A patent's expiry date may change depending upon legal activities going on that patent. Critical activities like abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease the life of a patent hence affecting its expiry date and in turn affecting the generic launch date of that drug. Tracking these ongoing activities on a patent application helps to keep an eye on the latest developments in the patent process of the drug which can give an idea of how early a drug's generic could be available. The next section provides a list of recent legal activities on Evoclin's patents.
Latest Legal Activities on Evoclin's Patents
Given below is the list of recent legal activities going on the following patents of Evoclin.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Payment of Maintenance Fee, 12th Year, Large Entity | 22 Oct, 2019 | US7374747 |
| Payment of Maintenance Fee, 12th Year, Large Entity | 13 Apr, 2018 | US7141237 |
| Entity Status Set To Undiscounted (Initial Default Setting or Status Change) | 17 Jan, 2012 | US7374747 |
| Entity Status Set To Undiscounted (Initial Default Setting or Status Change) | 29 Jul, 2010 | US7141237 |
| Correspondence Address Change Critical | 11 Sep, 2009 | US7374747 |
| Correspondence Address Change Critical | 11 Sep, 2009 | US7141237 |
| Patent Issue Date Used in PTA Calculation Critical | 20 May, 2008 | US7374747 |
| Recordation of Patent Grant Mailed Critical | 20 May, 2008 | US7374747 |
| Issue Notification Mailed Critical | 30 Apr, 2008 | US7374747 |
| Application Is Considered Ready for Issue Critical | 04 Apr, 2008 | US7374747 |
US patents provide insights into the exclusivity only within the United States, but Evoclin is protected by patents in multiple countries. Understanding the full scope of patent protection is crucial in strategizing market entry. By looking at the broader patent landscape, you can identify markets with weaker patent protection which could be ideal generic entry points. The following section offers details on Evoclin's family patents as well as insights into ongoing legal events on those patents.
Evoclin's Family Patents
Explore Our Curated Drug Screens
Generic Launch
Generic Release Date:
Evoclin's generic launch date based on the expiry of its last outstanding patent is estimated to be Feb 03, 2024 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)
Evoclin Generic API suppliers:
Clindamycin Phosphate is the generic name for the brand Evoclin. 42 different companies have already filed for the generic of Evoclin, with Hikma having the maximum number of approved applications. Check out the entire list of companies who have already received approval for Evoclin's generic
How can I launch a generic of Evoclin before its drug patent expiration? :
You can seek FDA approval to launch a generic drug before the expiration of Evoclin's patents related by providing a 'paragraph IV certification' in your application, which states that the patent submitted by the Evoclin's sponsor is invalid, unenforceable, or will not be infringed by your generic product.
Given below are the details of the already filed Para IV certificates on Evoclin -
| Strength | Submission Date | ANDA(s) Filed | First applicant approval | Last patent expiry | 180 day status |
|---|---|---|---|---|---|
| 0.01 | 1 | 31 Mar, 2010 | 09 Aug, 2026 | Eligible |
Alternative Brands for Evoclin
Evoclin which is used for treating acne vulgaris., has several other brand drugs using the same active ingredient (Clindamycin Phosphate). Given below is the list of those companies and their brand drugs, to help you identify new opportunities, assess competitors, and plan your market strategies more effectively.
| Drug Owner | Drug Name | |||||
|---|---|---|---|---|---|---|
| Almirall |
| |||||
| Bausch |
| |||||
| Organon Llc |
| |||||
| Padagis Us |
| |||||
| Pfizer |
| |||||
| Stiefel |
|
Apart from brand drugs containing the same ingredient, some generics have also been filed for Clindamycin Phosphate, Evoclin's active ingredient. Check the complete list of approved generic manufacturers for Evoclin
About Evoclin
Evoclin is a drug owned by Norvium Bioscience Llc. It is used for treating acne vulgaris. Evoclin uses Clindamycin Phosphate as an active ingredient. Evoclin was launched by Norvium Bioscience in 2004.
Approval Date:
Evoclin was approved by FDA for market use on 22 October, 2004.
Active Ingredient:
Evoclin uses Clindamycin Phosphate as the active ingredient. Check out other Drugs and Companies using Clindamycin Phosphate ingredient
Treatment:
Evoclin is used for treating acne vulgaris.
Dosage:
Evoclin is available in aerosol, foam form for topical use. Given below is detailed information on Dosage -
| Strength | Dosage Form | Availability | Application Pathway |
|---|---|---|---|
| 1% **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | AEROSOL, FOAM | Discontinued | TOPICAL |